A randomized, dose-ranging study of Alferon (R) LDO [low dose interferon alfa-n3 (human leukocyte derived)] in asymptomatic HIV+ subjects
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Interferon alpha-n3 (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors AIM ImmunoTech
- 16 Nov 2005 New trial record.